A Phase 2a Multiple Dose Basket Study of the Safety, Tolerability, and Pharmacologic Activity of BT200 in Patients With Hereditary Bleeding Disorders
Latest Information Update: 15 Sep 2023
At a glance
- Drugs BT 200 (Primary)
- Indications Haemophilia A; Von Willebrand disease
- Focus Therapeutic Use
- 15 Sep 2022 Results published in the Blood
- 10 Nov 2021 Status changed from recruiting to completed.
- 28 Dec 2020 New trial record